Published in Neoplasia on September 01, 2012
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia (2012) 0.89
The implication and potential applications of high-mobility group box 1 protein in breast cancer. Ann Transl Med (2016) 0.79
Cancer subclonal genetic architecture as a key to personalized medicine. Neoplasia (2013) 0.78
Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice. Br J Pharmacol (2016) 0.77
IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget (2016) 0.75
Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One (2017) 0.75
HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol (2011) 6.23
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci (2009) 3.59
Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol (2006) 2.44
Targeted therapies for breast cancer. J Clin Invest (2011) 2.22
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res (2005) 2.08
Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta (2009) 2.07
High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem (2010) 1.79
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (2010) 1.74
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res (2005) 1.74
Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ (2008) 1.73
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer (2011) 1.65
Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol (2005) 1.59
Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer (2011) 1.51
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol (2009) 1.40
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol (2011) 1.34
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol (2010) 1.25
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res (2007) 1.23
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer (2008) 1.20
Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci (2010) 1.16
Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol (2008) 1.15
The role of autophagy in sensitizing malignant glioma cells to radiation therapy. Acta Biochim Biophys Sin (Shanghai) (2009) 1.10
Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One (2012) 1.09
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer. Immunol Cell Biol (2011) 1.05
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett (2009) 1.04
Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy (2009) 1.03
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol (2011) 1.03
Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells. Oncogene (2007) 1.03
MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunol Immunother (2011) 1.03
Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther (2010) 1.03
Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res (2009) 1.02
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol (2010) 1.01
The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy (2010) 1.00
The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis. Clin Cancer Res (2006) 1.00
BORIS in human cancers -- a review. Eur J Cancer (2011) 0.98
Signal transduction therapy of cancer. Mol Aspects Med (2010) 0.98
Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Exp Cell Res (2005) 0.97
Drugs interfering with apoptosis in breast cancer. Curr Pharm Des (2011) 0.94
Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol (2011) 0.94
Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses. Hum Vaccin (2011) 0.93
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93
Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol (2009) 0.92
Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med (2011) 0.90
HMGB1 and microparticles as mediators of the immune response to cell death. Antioxid Redox Signal (2011) 0.90
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL. Invest New Drugs (2011) 0.89
Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res Treat (2009) 0.89
Differential effects of Paclitaxel on dendritic cell function. BMC Immunol (2010) 0.88
BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas. PLoS One (2010) 0.88
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol (2010) 0.86
Combining emerging agents in advanced breast cancer. Oncologist (2011) 0.83
Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med (2008) 0.83
Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells. J Urol (2010) 0.82
Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chem Biol Interact (2008) 0.82
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J Med Chem (2008) 0.81
Systemic cell-cycle suppression by Apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells. Int J Mol Med (2009) 0.81
Potentiation strategies of dendritic cell-based antitumor vaccines: combinational therapy takes the front seat. Drug Discov Today (2011) 0.79
Susceptibility for breast cancer in young patients with short rare minisatellite alleles of BORIS. BMB Rep (2010) 0.79
Manipulation of MHC-I/TCR interaction for immune therapy. Cell Mol Immunol (2008) 0.78
ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J Exp Med (2002) 2.92
Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 2.59
Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res (2005) 2.11
The pancreatic ductal epithelium serves as a potential pool of progenitor cells. Pediatr Diabetes (2004) 2.06
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst (2004) 2.02
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res (2007) 1.86
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (2010) 1.74
Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol (2005) 1.71
Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol (2002) 1.63
A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med (2004) 1.59
HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med (2002) 1.59
The feedback phase of type I interferon induction in dendritic cells requires interferon regulatory factor 8. Immunity (2007) 1.53
Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie (2007) 1.48
Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis. J Virol (2004) 1.39
Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS (2003) 1.37
IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol (2006) 1.36
Transdifferentiation of pancreatic ductal cells to endocrine beta-cells. Biochem Soc Trans (2008) 1.30
Immune surveillance properties of human NK cell-derived exosomes. J Immunol (2012) 1.26
Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes (2006) 1.25
Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One (2011) 1.24
Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer (2009) 1.23
ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. Blood (2003) 1.21
Antitumour effects of antiretroviral therapy. Nat Rev Cancer (2004) 1.20
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer (2009) 1.18
Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res (2010) 1.16
Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res (2011) 1.13
IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell differentiation by repressing Foxp3 expression. J Immunol (2008) 1.12
Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance. J Biol Chem (2007) 1.12
Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol (2005) 1.11
Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes. Eur J Immunol (2008) 1.10
The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity. J Interferon Cytokine Res (2002) 1.10
Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity (2010) 1.10
Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J Exp Med (2003) 1.09
LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood (2009) 1.09
Mycobacterium tuberculosis subverts the differentiation of human monocytes into dendritic cells. Eur J Immunol (2002) 1.08
The tumor microenvironment: a pitch for multiple players. Front Oncol (2013) 1.07
IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood (2011) 1.07
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res (2006) 1.06
Monocyte/macrophage-derived CC chemokines and their modulation by HIV-1 and cytokines: a complex network of interactions influencing viral replication and AIDS pathogenesis. J Leukoc Biol (2003) 1.05
Inhibition of phosphatidylcholine-specific phospholipase C results in loss of mesenchymal traits in metastatic breast cancer cells. Breast Cancer Res (2012) 1.04
Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev (2007) 1.04
Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol (2011) 1.04
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care (2004) 1.03
Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev (2002) 1.03
Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine (2005) 1.03
A two-year follow-up of psychodynamic psychotherapy for internalizing disorders in children. J Am Acad Child Adolesc Psychiatry (2003) 1.02
Dendritic cells derived from BCG-infected precursors induce Th2-like immune response. J Leukoc Biol (2004) 1.01
Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J Immunol (2004) 1.01
IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology (2010) 1.01
Triacsin C inhibits the formation of 1H NMR-visible mobile lipids and lipid bodies in HuT 78 apoptotic cells. Biochim Biophys Acta (2003) 1.01
Phosphatidylcholine-specific phospholipase C in mitogen-stimulated fibroblasts. Exp Cell Res (2004) 1.01
Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. Lab Chip (2012) 1.01
Type I IFN protects permissive macrophages from Legionella pneumophila infection through an IFN-gamma-independent pathway. J Immunol (2004) 1.01
APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J Immunol (2010) 1.00
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia (2012) 0.99
Identification of markers for newly formed beta-cells in the perinatal period: a time of recognized beta-cell immaturity. J Histochem Cytochem (2010) 0.99
Endogenous PGE2 promotes the induction of human Th17 responses by fungal ß-glucan. J Leukoc Biol (2010) 0.98
HIV-1 Nef triggers Vav-mediated signaling pathway leading to functional and morphological differentiation of dendritic cells. FASEB J (2003) 0.98
Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. Mol Cell Neurosci (2010) 0.98
IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb Exp Pharmacol (2009) 0.97
Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann N Y Acad Sci (2010) 0.97
Sociodemographic, clinical and organisational factors associated with delayed hospital discharges: a cross-sectional study. BMC Health Serv Res (2014) 0.97
Type I IFN regulate DC turnover in vivo. Eur J Immunol (2009) 0.96
Interferon-α as antiviral and antitumor vaccine adjuvants: mechanisms of action and response signature. J Interferon Cytokine Res (2012) 0.95
Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. Clin Cancer Res (2013) 0.95
Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells. Eur J Immunol (2007) 0.95
Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels. Eur Heart J (2005) 0.94
Loss of type I IFN receptors and impaired IFN responsiveness during terminal maturation of monocyte-derived human dendritic cells. J Immunol (2002) 0.94
IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. Expert Rev Vaccines (2011) 0.93
Candida albicans yeast and germ tube forms interfere differently with human monocyte differentiation into dendritic cells: a novel dimorphism-dependent mechanism to escape the host's immune response. Infect Immun (2004) 0.93
Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res (2010) 0.93
beta-Glucan of Candida albicans cell wall causes the subversion of human monocyte differentiation into dendritic cells. J Leukoc Biol (2007) 0.92